Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies

Payam Mohassel, Andrew L. Mammen

Research output: Contribution to journalReview articlepeer-review

94 Scopus citations


Statins are among the most commonly prescribed medications that significantly reduce cardiovascular risk in selected individuals. However, these drugs can also be associated with muscle symptoms ranging from mild myalgias to severe rhabdomyolysis. Although statin myotoxicity is usually self-limited, in some instances statin-exposed subjects can develop an autoimmune myopathy typically characterized by progressive weakness, muscle enzyme elevations, a necrotizing myopathy on muscle biopsy, and autoantibodies that recognize 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the pharmacologic target of statins. These antibodies are also found in some autoimmune myopathy patients without statin exposure. Importantly, anti-HMGCR antibodies are not found in the vast majority of statin-exposed subjects without autoimmune myopathy, including those with self-limited statin intolerance. Thus, testing for these antibodies may help differentiate those with self-limited statin myopathy who recover after statin discontinuation from those with a progressive statin-associated autoimmune myopathy who typically require immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalMuscle and Nerve
Issue number4
StatePublished - Oct 2013


  • Autoantibodies
  • HMG-CoA reductase
  • Myopathy
  • Myositis
  • Necrotizing
  • Statins

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)
  • Cellular and Molecular Neuroscience
  • Physiology


Dive into the research topics of 'Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies'. Together they form a unique fingerprint.

Cite this